**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 66-year-old woman developed nausea, vomiting, abdominal pain and diarrhoea following off-label treatment with lopinavir/ritonavir and ribavirin for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.

The woman returned to Poland on 29 February 2020 after a 2 week stay at her friend\'s house in Italy. On 7 March 2020, she experienced loss of appetite and taste, nausea and diffuse abdominal and back pain. Based on the clinical and laboratory findings, SARS-CoV-2 infection was suspected, and she was admitted to the department of infectious diseases on 15 March 2020. On admission, no dyspnoea or fever was observed; however, mild dry cough appeared. A nasopharyngeal swab specimen was found to be positive for SARS-CoV-2. She was also found to have pneumonia. She started receiving oxygen therapy, amoxicillin/clavulanic acid, drotaverine and azithromycin. During her hospital stay, abdominal pain subsided, slight dyspnoea appeared and dry and paroxysmal cough intensified. As her condition continued to deteriorate, experimental treatment (off-label treatment) with lopinavir/ritonavir 500mg twice a day with ribavirin 1000 mg/day (400mg+600mg) \[*routes not stated*\] was started on 21 March 2020. However, she developed nausea, vomiting, abdominal pain and diarrhoea secondary to the lopinavir/ritonavir and ribavirin therapy.

The woman\'s therapy with lopinavir/ritonavir and ribavirin was stopped after 3 days (i.e on 24 March 2020). As a result, her symptoms vanished immediately, and her general condition improved significantly. On 25−27 March 2020, she was found to be in good condition and did not report any significant symptoms. On 29 March 2020, another swab specimen was found to be negative for SARS-CoV-2, and she was scheduled to be discharged in the subsequent days.
